Bile acid therapy for primary biliary cholangitis: Pathogenetic validation

doi:10.5493/wjem.v15.i1.101771

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1214)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series.

Item

Count

PDF

HTML

590

Figures (1-4)

169

Sum=807

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

186

Sum=274

Publishing Process of This Article

Item

Count

Browse

Download

Sum=69

Mar 20, 2025 (publication date) through Mar 25, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Experimental Medicine

ISSN

2220-315x

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Exp Med. Mar 20, 2025; 15(1): 101771
Published online Mar 20, 2025. doi: 10.5493/wjem.v15.i1.101771

Full Size Figure Download Figure

Figure 4 Cholehepatic bypass and metabolism of norursodeoxycholic acid glucuronide. norUDCA: Norursodeoxycholic acid glucuronide; MRP: Multidrug-resistance protein.

Citation: Reshetnyak VI, Maev IV. Bile acid therapy for primary biliary cholangitis: Pathogenetic validation. World J Exp Med 2025; 15(1): 101771
URL: https://www.wjgnet.com/2220-315x/full/v15/i1/101771.htm
DOI: https://dx.doi.org/10.5493/wjem.v15.i1.101771